GZBL(SZ:002424) Zheng Quan Shi Bao Wang·2025-06-27 03:42Core Viewpoint - ST Bailin has successfully applied to remove other risk warnings, allowing it to "delist" from the ST designation and resume normal trading conditions [2][3] Group 1: Company Announcement - ST Bailin's stock will be suspended for one day on June 27 and will resume trading on June 30, 2025, with its name changing from "ST Bailin" to "Guizhou Bailin" [2] - The daily price fluctuation limit will increase from 5% to 10% following the removal of risk warnings [2] Group 2: Internal Control and Financial Performance - In 2023, ST Bailin received a negative opinion on its internal control audit report from Tianjian Accounting Firm, leading to the imposition of risk warnings [2] - For 2024, ST Bailin has received a qualified opinion on its internal control audit report, indicating that the issues from the previous year have been resolved [3] - The company reported a total revenue of 3.825 billion yuan in 2024, a year-on-year decrease of 10.26%, but achieved a net profit of 33.62 million yuan, marking a turnaround from losses [3] Group 3: Product and Market Position - ST Bailin specializes in the research, production, and sales of苗药 (苗药 refers to traditional Chinese medicine), with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup [3] - The company holds significant market shares in cardiovascular, cough, cold, and pediatric medicine sectors [3] - The "Bailing Bird" trademark products cover various medical fields and have achieved over 100 million yuan in sales in major markets [3] Group 4: Future Outlook - Following the completion of internal control reforms, ST Bailin aims to refocus on its core business, deepen reforms, and strengthen its leading position in苗药 [4] - The company plans to accelerate new drug development and market expansion for long-term stable growth [4]